Literature DB >> 17489740

Identification of a novel 82 kDa proMMP-9 species associated with the surface of leukaemic cells: (auto-)catalytic activation and resistance to inhibition by TIMP-1.

Christian Ries1, Thomas Pitsch, Reinhard Mentele, Stefan Zahler, Virginia Egea, Hideaki Nagase, Marianne Jochum.   

Abstract

MMP-9 (matrix metalloproteinase 9) plays a critical role in tumour progression. Although the biochemical properties of the secreted form of proMMP-9 are well characterized, little is known about the function and activity of cell surface-associated proMMP-9. We purified a novel 82 kDa species of proMMP-9 from the plasma membrane of THP-1 leukaemic cells, which has substantial differences from the secreted 94 kDa proMMP-9. The 82 kDa form was not detected in the medium even upon stimulation with a phorbol ester. It is truncated by nine amino acid residues at its N-terminus, lacks O-linked oligosaccharides present in the 94 kDa proMMP-9, but retains N-linked carbohydrates. Incubation of 94 kDa proMMP-9 with MMP-3 generated the well-known 82 kDa active form, but the 82 kDa proMMP-9 was converted into an active species of 35 kDa, which was also produced by autocatalytic processing in the absence of activating enzymes. The activated 35 kDa MMP-9 efficiently degraded gelatins, native collagen type IV and fibronectin. The enzyme was less sensitive to TIMP-1 (tissue inhibitor of metalloproteinase 1) inhibition with IC50 values of 82 nM compared with 1 nM for the 82 kDa active MMP-9. The synthetic MMP inhibitor GM6001 blocked the activity of both enzymes, with similar IC50 values below 1 nM. The 82 kDa proMMP-9 is also produced in HL-60 and NB4 leukaemic cell lines as well as ex vivo leukaemic blast cells. It is, however, absent from neutrophils and mononuclear cells isolated from peripheral blood of healthy individuals. Thus, the 82 kDa proMMP-9 expressed on the surface of malignant cells may escape inhibition by natural TIMP-1, thereby facilitating cellular invasion in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17489740      PMCID: PMC2267301          DOI: 10.1042/BJ20070191

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  56 in total

1.  Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion.

Authors:  N Ramos-DeSimone; E Hahn-Dantona; J Sipley; H Nagase; D L French; J P Quigley
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

2.  High affinity binding of latent matrix metalloproteinase-9 to the alpha2(IV) chain of collagen IV.

Authors:  M W Olson; M Toth; D C Gervasi; Y Sado; Y Ninomiya; R Fridman
Journal:  J Biol Chem       Date:  1998-04-24       Impact factor: 5.157

3.  Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles.

Authors:  M Nguyen; J Arkell; C J Jackson
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

4.  Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metalloproteinases.

Authors:  W Huang; Q Meng; K Suzuki; H Nagase; K Brew
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

5.  Expression of human pro-matrix metalloproteinase 3 that lacks the N-terminal 34 residues in Escherichia coli: autoactivation and interaction with tissue inhibitor of metalloproteinase 1 (TIMP-1).

Authors:  K Suzuki; C C Kan; W Hung; M R Gehring; K Brew; H Nagase
Journal:  Biol Chem       Date:  1998-02       Impact factor: 3.915

6.  Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion.

Authors:  Q Yu; I Stamenkovic
Journal:  Genes Dev       Date:  1999-01-01       Impact factor: 11.361

7.  CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells.

Authors:  L Y Bourguignon; Z Gunja-Smith; N Iida; H B Zhu; L J Young; W J Muller; R D Cardiff
Journal:  J Cell Physiol       Date:  1998-07       Impact factor: 6.384

8.  The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism.

Authors:  A J Barrett; P M Starkey
Journal:  Biochem J       Date:  1973-08       Impact factor: 3.857

9.  Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing.

Authors:  U Schönbeck; F Mach; P Libby
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

10.  Autocrine regulation of matrix metalloproteinase-9 gene expression and secretion by tumor necrosis factor-alpha (TNF-alpha) in NB4 leukemic cells: specific involvement of TNF receptor type 1.

Authors:  M G Ismair; C Ries; F Lottspeich; C Zang; H J Kolb; P E Petrides
Journal:  Leukemia       Date:  1998-07       Impact factor: 11.528

View more
  13 in total

1.  BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts.

Authors:  Q Li; Y Wu; S Fang; L Wang; H Qi; Y Zhang; J Zhang; W Li
Journal:  Cancer Gene Ther       Date:  2015-04-03       Impact factor: 5.987

2.  Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains.

Authors:  Vishnu C Ramani; Gur P Kaushal; Randy S Haun
Journal:  Biochim Biophys Acta       Date:  2011-05-17

3.  Molecular biological characteristics of the recruitment of hematopoietic stem cells from bone marrow niche in chronic myeloid leukemia.

Authors:  Biao Zhu; Jianbo Zhang; Jiao Chen; Chenglong Li; Xiaodong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.

Authors:  Z Xishan; L Xianjun; L Ziying; C Guangxin; L Gang
Journal:  Cancer Gene Ther       Date:  2014-09-12       Impact factor: 5.987

5.  MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides.

Authors:  Joseph D Raffetto; Yaskara V R Barros; Amanda K Wells; Raouf A Khalil
Journal:  J Surg Res       Date:  2008-10-24       Impact factor: 2.192

6.  RECK (reversion-inducing cysteine-rich protein with Kazal motifs) regulates migration, differentiation and Wnt/β-catenin signaling in human mesenchymal stem cells.

Authors:  Christian Mahl; Virginia Egea; Remco T A Megens; Thomas Pitsch; Donato Santovito; Christian Weber; Christian Ries
Journal:  Cell Mol Life Sci       Date:  2015-10-12       Impact factor: 9.261

7.  Let-7f miRNA regulates SDF-1α- and hypoxia-promoted migration of mesenchymal stem cells and attenuates mammary tumor growth upon exosomal release.

Authors:  Virginia Egea; Kai Kessenbrock; Devon Lawson; Alexander Bartelt; Christian Weber; Christian Ries
Journal:  Cell Death Dis       Date:  2021-05-20       Impact factor: 8.469

8.  The research on the immuno-modulatory defect of mesenchymal stem cell from Chronic Myeloid Leukemia patients.

Authors:  Zhu Xishan; An Guangyu; Song Yuguang; Zhang Hongmei
Journal:  J Exp Clin Cancer Res       Date:  2011-05-02

9.  Matrix metalloproteinases in the mouse retina: a comparative study of expression patterns and MMP antibodies.

Authors:  Lies De Groef; Lien Andries; Kim Lemmens; Inge Van Hove; Lieve Moons
Journal:  BMC Ophthalmol       Date:  2015-12-29       Impact factor: 2.209

10.  The Anti-inflammatory Role of Endometase/Matrilysin-2 in Human Prostate Cancer Cells.

Authors:  Zahraa I Khamis; Diego A R Zorio; Leland W K Chung; Qing-Xiang Amy Sang
Journal:  J Cancer       Date:  2013-03-20       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.